This is a randomized phase II trial evaluating the efficacy of a nivolumab monotherapy lead in "window" or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers.

    Trial Coordinator
    Meredith Kissel

    Monitor
    Belen Hahn, Michael Wiedemann, Giuseppe Achille, Daniela Celotto

    Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

    IBCSG Data Management Center/Frontier Science Foundation
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Targeted Accrual
    108

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login